Veterinary Medicine Program

Neuronascent (NNI) Receives IACUC Approval to Begin Treatment of Aged Dogs with Probable Canine Cognitive Dysfunction (CCD) in Fairbanks, Alaska Using NNI’s Novel Neuron Regenerative Therapy – Cajuvenate

Neuronascent and the University of Alaska – Fairbanks (UAF) are working together to test and treat older sled dogs and canine pets that have probable Canine Cognitive Dysfunction (CCD) a similar disorder to Alzheimer’s disease observed in humans. The study has been approved by a UAF ethics board and will begin to identify and sign up owners with their aged dogs that have significant behavioral issues. Once identified the owners will work with their own veterinarian and potentially be given the Cajuvenate therapeutic for daily oral administration for up to a 6-month period. Cajuvenate, a novel therapy discovered at Neuronascent has already shown ability in several rodent models to promote new neurons in aged and diseased brains that then reverse the behavioral deficits back to young and normal rodents. The therapeutic, already shown safe in many species will be administered at the lowest efficacious dose. This trial to begin in Alaska may appear to be in reverse order, for normally we cure human’s first, but with the extensive time, cost and regulatory hurdles of human efficacy trials, now we will attempt to cure our “best friends” first.

Laika: First into Space
Your Pet: First to be Cured of Alzheimer’s/CCD?